PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19005461-0	2009	Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.	Dronabinol	53-80	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	120-126	
19005461-1	2009	The impact of the CYP2C9 polymorphism on the pharmacokinetics of orally administered 9-tetrahydrocannabinol (THC) was studied in 43 healthy volunteers.	Dronabinol	85-107	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	18-24	
19005461-3	2009	However, the median area under the curve of THC was threefold higher and that of 11-nor-9-carboxy-9-tetrahydrocannabinol was 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes.	Dronabinol	44-47	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	138-144	
19005461-4	2009	CYP2C9*3 carriers also showed a trend toward increased sedation following administration of THC.	Dronabinol	92-95	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	0-6	
19005461-5	2009	Therefore, the CYP2C9*3 variant may influence both the therapeutic and adverse effects of THC.	Dronabinol	90-93	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	15-21